Timing of SGLT2i initiation after acute myocardial infarction.
Clinical trial
Myocardial infarction
SGLT2i
Timing
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
30 09 2023
30 09 2023
Historique:
received:
28
07
2023
accepted:
19
09
2023
medline:
2
10
2023
pubmed:
1
10
2023
entrez:
30
9
2023
Statut:
epublish
Résumé
Pharmacological post-MI treatment is routinely initiated at intensive/cardiac care units. However, solid evidence for an early start of these therapies is only available for dual platelet therapy and statins, whereas data on beta blockers and RAAS inhibitors are heterogenous and mainly limited to STEMI and heart failure patients. Recently, the EMMY trial provided the first evidence on the beneficial effects of SGLT2 inhibitors (SGLT2i) when initiated early after PCI. In patients with type 2 diabetes mellitus, SGLT2i are considered "sick days drugs" and it, therefore, remains unclear if very early SGLT2i initiation following MI is as safe and effective as delayed initiation. The EMMY trial evaluated the effect of empagliflozin on NT-proBNP and functional and structural measurements. Within the Empagliflozin group, 22 (9.5%) received early treatment (< 24 h after PCI), 98 (42.2%) within a 24 to < 48 h window (intermediate), and 111 (48.1%) between 48 and 72 h (late). NT-proBNP levels declined by 63.5% (95%CI: - 69.1; - 48.1) in the early group compared to 61.0% (- 76.0; - 41.4) in the intermediate and 61.9% (- 70.8; - 45.7) in the late group (n.s.) within the Empagliflozin group with no significant treatment groups-initiation time interaction (p Very early administration of SGLT2i after acute myocardial infarction does not show disadvantageous signals with respect to safety and appears to be as effective in reducing NT-proBNP as well as improving structural and functional LV markers as initiation after 2-3 days.
Sections du résumé
BACKGROUND
Pharmacological post-MI treatment is routinely initiated at intensive/cardiac care units. However, solid evidence for an early start of these therapies is only available for dual platelet therapy and statins, whereas data on beta blockers and RAAS inhibitors are heterogenous and mainly limited to STEMI and heart failure patients. Recently, the EMMY trial provided the first evidence on the beneficial effects of SGLT2 inhibitors (SGLT2i) when initiated early after PCI. In patients with type 2 diabetes mellitus, SGLT2i are considered "sick days drugs" and it, therefore, remains unclear if very early SGLT2i initiation following MI is as safe and effective as delayed initiation.
METHODS AND RESULTS
The EMMY trial evaluated the effect of empagliflozin on NT-proBNP and functional and structural measurements. Within the Empagliflozin group, 22 (9.5%) received early treatment (< 24 h after PCI), 98 (42.2%) within a 24 to < 48 h window (intermediate), and 111 (48.1%) between 48 and 72 h (late). NT-proBNP levels declined by 63.5% (95%CI: - 69.1; - 48.1) in the early group compared to 61.0% (- 76.0; - 41.4) in the intermediate and 61.9% (- 70.8; - 45.7) in the late group (n.s.) within the Empagliflozin group with no significant treatment groups-initiation time interaction (p
CONCLUSION
Very early administration of SGLT2i after acute myocardial infarction does not show disadvantageous signals with respect to safety and appears to be as effective in reducing NT-proBNP as well as improving structural and functional LV markers as initiation after 2-3 days.
Identifiants
pubmed: 37777743
doi: 10.1186/s12933-023-02000-5
pii: 10.1186/s12933-023-02000-5
pmc: PMC10544140
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
empagliflozin
HDC1R2M35U
Banques de données
ClinicalTrials.gov
['NCT03087773']
EudraCT
['2016-004591-22']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
269Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Pharmacol Res. 2023 Jan;187:106597
pubmed: 36470546
Am Heart J. 2022 Nov;253:86-98
pubmed: 35595091
Nat Med. 2022 Mar;28(3):568-574
pubmed: 35228754
Crit Care. 2023 May 16;27(1):189
pubmed: 37194077
Eur Heart J. 2022 Nov 1;43(41):4421-4432
pubmed: 36036746
Circulation. 2013 Oct 1;128(14):1495-503
pubmed: 24002794
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Cardiovasc Diabetol. 2023 Apr 13;22(1):86
pubmed: 37055837
BMC Med. 2023 Feb 24;21(1):71
pubmed: 36829203
Clin Res Cardiol. 2006 May;95(5):270-80
pubmed: 16598393
Cardiovasc Diabetol. 2023 Jul 20;22(1):184
pubmed: 37475009
Diabetes Care. 2021 Jan;44(Suppl 1):S211-S220
pubmed: 33298426
Cardiovasc Diabetol. 2023 Apr 1;22(1):80
pubmed: 37005586
Cardiovasc Diabetol. 2023 Jul 5;22(1):166
pubmed: 37407956
ESC Heart Fail. 2021 Dec;8(6):4852-4862
pubmed: 34716749
JAMA. 2009 Aug 19;302(7):767-73
pubmed: 19690309
Clin Chim Acta. 2012 May 18;413(9-10):888-93
pubmed: 22333672
Diabetes Obes Metab. 2022 Nov;24(11):2071-2080
pubmed: 35801339